ICU Medical (ICUI) Projected to Release Quarterly Earnings on Thursday

ICU Medical (NASDAQ:ICUI) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect ICU Medical to post earnings of $2.14 per share and revenue of $552.03 million for the quarter. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The business had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same period in the prior year, the business earned $2.10 EPS. The firm’s revenue for the quarter was up .5% on a year-over-year basis. On average, analysts expect ICU Medical to post $7.22 EPS for the current fiscal year and $8.05 EPS for the next fiscal year.

ICU Medical Price Performance

Shares of ICUI opened at $162.38 on Tuesday. ICU Medical has a 12-month low of $113.37 and a 12-month high of $192.85. The business’s fifty day moving average is $163.81 and its 200 day moving average is $148.96. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.06 billion, a P/E ratio of 137.61, a P/E/G ratio of 2.09 and a beta of 0.86.

Insiders Place Their Bets

In other ICU Medical news, COO Christian Voigtlander sold 8,929 shares of ICU Medical stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the completion of the sale, the chief operating officer directly owned 37,377 shares in the company, valued at $6,837,374.61. The trade was a 19.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ben Sousa sold 2,250 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total transaction of $401,220.00. Following the completion of the transaction, the insider owned 3,076 shares of the company’s stock, valued at $548,512.32. This trade represents a 42.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 21,830 shares of company stock worth $3,905,003 over the last quarter. Insiders own 2.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ICUI. Weiss Ratings upgraded shares of ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Zacks Research downgraded ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Piper Sandler boosted their price objective on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. BTIG Research upped their price objective on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 target price on shares of ICU Medical in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, ICU Medical has an average rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.